Neutrophil to lymphocyte ratio is a strong predictor of tumor recurrence in early colon cancers: A propensity score-matched analysis

Surgery (United States)

Volumn 158, Issue 1, 2015, Pages 112-120

  Galizia, Gennaro ^a   Lieto, Eva ^a   Zamboli, Anna ^a   De Vita, Ferdinando ^b   Castellano, Paolo ^a   Romano, Ciro ^a   Auricchio, Annamaria ^a   Cardella, Francesca ^a   De Stefano, Lorenzo ^a   Orditura, Michele ^b  

^a SECOND UNIVERSITY OF NAPLES   (Italy)

^b Medical Oncology   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CARCINOEMBRYONIC ANTIGEN;

ADJUVANT THERAPY; ADULT; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER PATIENT; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER SIZE; CANCER SURGERY; CANCER SURVIVAL; COLON CANCER; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; DISEASE FREE SURVIVAL; EARLY CANCER; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; NEUTROPHIL LYMPHOCYTE RATIO; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; PROPENSITY SCORE; PROTEIN BLOOD LEVEL; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY; TUMOR VOLUME; BLOOD; COLON TUMOR; LEUKOCYTE COUNT; LYMPHOCYTE; NEUTROPHIL; PATHOLOGY; PREDICTIVE VALUE; PROGNOSIS; TUMOR RECURRENCE;

AGED; COLONIC NEOPLASMS; FEMALE; HUMANS; LEUKOCYTE COUNT; LYMPHOCYTES; MALE; NEOPLASM RECURRENCE, LOCAL; NEUTROPHILS; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROPENSITY SCORE; ROC CURVE;

EID: 84938701066     PISSN: 00396060     EISSN: 15327361     Source Type: Journal    
DOI: 10.1016/j.surg.2015.02.006     Document Type: Article

References (33)

1. Siegel R, Ma J, Zou Z, Jemal A Cancer Statistics, 2014. CA Cancer J Clin 2014;64:9-29.
2. Van Cutsem E, Cervantes A, Nordlinger B, Arnold D. Metastatic colorectal cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 2014(Suppl 3): iii1-9.
3. Astler VB, Coller FA. The prognostic significance of direct extension of carcinoma of the colon rectum. Ann Surg 1954;139:846-52.
4. Sobin LH, Gospodarowicz MK, Wittekind C. International Union Against Cancer (UICC) TNM classification of malignant tumors. 7th ed. New York: Wiley-Liss; 2010.
5. Labianca R, Nordlinger B, Beretta GD, Mosconi S, Mandala M, Cervantes A, et al. Early colon cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 2013;24(Suppl. 6): vi64-72.
6. Kumar A, Kennecke HF, Renouf DJ, Lim HJ, Gill S, Woods R, et al. Adjuvant chemotherapy use and outcomes of patients with high-risk versus low-risk stage II colon cancer. Cancer 2015;121:527-34.
7. Lan YT, Chang SC, Yang SH, Lin CC, Wang HS, Jiang JK, et al. Comparison of clinicopathological characteristics and prognosis between early and late recurrence after curative surgery for colorectal cancer. Am J Surg 2014;207:922-30.
8. Ryuk JP, Choi GS, Park JS, Kim HJ, Park SY, Yoon GS, et al. Predictive factors and the prognosis of recurrence of colorectal cancer within 2 years after curative resection. Ann Surg Treat Res 2014;86:143-51.
9. Li MX, Liu XM, Zhang XF, Zhang JF, Wang WL, Zhu Y, et al. Prognostic role of neutrophil-to-lymphocyte ratio in colorectal cancer: A systematic review and meta-analysis. Int J Cancer 2014;134:2403-13.
10. Grivennikov SI, Greten FR, Karin M. Immunity, inflammation, and cancer. Cell 2010;140:883-99.
11. O'Callaghan DS, O'Donnell D, O'Connell F, O'Byrne KJ. The role of inflammation in the pathogenesis of non-small cell lung cancer. J Thorac Oncol 2010;5:2024-36.
12. Galizia G, Orditura M, Romano C, Lieto E, Castellano P, Pelosio L, et al. Prognostic significance of circulating IL-10 and IL-6 serum levels in colon cancer patients undergoing surgery. Clin Immunol 2002;102:169-78.
13. McMillan DC. The systemic inflammation-based Glasgow prognostic score: a decade of experience in patients with cancer. Cancer Treat Rev 2013;39:534-40.
14. Mei Z, Liu Y, Cui A, Liang Z, Wang G, Peng H, et al. Tumor-infiltrating inflammation and prognosis in colorectal cancer: systematic review and meta-analysis. Br J Cancer 2014;110:1595-605.
15. Templeton AJ, McNamara MG, Seruga B, Seruga B, Vera-Badillo FE, Aneja P, et al. Prognostic role of neutrophil-to-lymphocyte ratio in solid tumors: a systematic review and meta-analysis. J Natl Cancer Inst 2014;106:dju124.
16. Hung HY, Chen JS, Yeh CY, Changchien CR, Tang R, Hsieh PS, et al. Effect of preoperative neutrophil-lymphocyte ratio on the surgical outcomes of stage II colon cancer patients who do not receive adjuvant chemotherapy. Int J Colorectal Dis 2011;26:1059-65.
17. Malietzis G, Giacometti M, Askari A, Nachiappan S, Kennedy RH, Faiz OD, et al. A preoperative neutrophil to lymphocyte ratio of 3 predicts disease-free survival after curative elective colorectal cancer surgery. Ann Surg 2014;260:287-92.
18. Leitch EF, Chakrabarti M, Crozier JE, McKee RF, Anderson JH, Horgan PG, et al. Comparison of the prognostic value of selected markers of the systemic inflammatory response in patients with colorectal cancer. Br J Cancer 2007;97:1266-70.
19. Lonjon G, Boutron I, Trinquart L, Ahmad N, Aim F, Nizard R, et al. Comparison of treatment effect estimates from prospective nonrandomized studies with propensity score analysis and randomized controlled trials of surgical procedures. Ann Surg 2014;259:18-25.
20. De Mestier L, Neuzillet C, Pozet A, Desot E, Deguelte-Lardiere S, Volet J, et al. Is primary tumor resection associated with a longer survival in colon cancer and unresectable synchronous metastases? A 4-year multicentre experience. Eur J Surg Oncol 2014;40:685-91.
21. Lim SH, Chua W, Cheng C, Descallar J, Ng W, Solomon M, et al. Effect of neoadjuvant chemoradiation on tumor-infiltrating/associated lymphocytes in locally advanced rectal cancers. Anticancer Res 2014;34:6505-13.
22. Clavien PA, Barkun J, De Oliveira ML, Vauthey JN, Dindo D, Schulick RD, et al. The Clavien-Dindo classification of surgical complications: five-year experience. Ann Surg 2009;250:187-96.
23. West SG, Cham H, Thoemmes F, Renneberg B, Schulze J, Weiler M. Propensity scores as a basis for equating groups: basic principles and application in clinical treatment outcome research. J Consult Clin Psychol 2014;82:906-19.
24. Hari DM, Leung AM, Lee JH, Sim MS, Vuong B, Chiu CG, et al. AJCC cancer staging manual 7 edition criteria for colon cancer: do the complex modifications improve prognostic assessment? J Am Coll Surg 2013;217:181-90.
25. Coussens LM, Werb Z. Inflammation and cancer. Nature 2002;420:860-7.
26. Chua W, Charles KA, Baracos VE, Clarke SJ. Neutrophil/lymphocyte ratio predicts chemotherapy outcomes in patients with advanced colorectal cancer. Br J Cancer 2011;104:1288-95.
27. Sellitto A, Galizia G, De Fanis U, Lieto E, Zamboli A, Orditura M, et al. Behavior of circulating CD4+CD25+Foxp3+ regulatory T cells in colon cancer patients undergoing surgery. J Clin Immunol 2011;31:1095-104.
28. Malietzis G, Giacometti M, Kennedy RH, Athanasiou T, Aziz O, Jenkins JT The emerging role of neutrophil to lymphocyte ratio in determining colorectal cancer treatment outcomes: a systematic review and meta-analysis. Ann Surg Oncol 2014;21:3938-46.
29. Ding PR, An X, Zhang RX, Fang YJ, Li LR, Chen G, et al. Elevated preoperative neutrophil to lymphocyte ratio predicts risk of recurrence following curative resection for stage IIA colon cancer. IntJ Colorectal Dis 2010;25:1427-33.
30. Urrejola G, Bambs CE, Espinoza MA, Gellona J, Zuniga AM, Molina ME, et al. An elevated neutrophil/lymphocyte ratio is associated with poor prognosis in stage II resected colon cancer. Rev Med Chil 2013;141:602-8.
31. Aggarwal BB, Vijayalekshmi RV, Sung B. Targeting inflammatory pathways for prevention and therapy of cancer: short-term friend, long-term foe. Clin Cancer Res 2009;15:425-30.
32. Lönnroth C, Andersson M, Asting AG, Nordgren S, Lundholm K. Preoperative low dose NSAID treatment influences the genes for stemness, growth, invasion and metastasis in colorectal cancer. Int J Oncol 2014;45:2208-20.
33. Sargent DJ, Marsoni S, Monges G, Thibodeau SN, Labianca R, Hamilton SR, et al. Defective mismatch repair as a predictive marker for lack of efficacy of fluorouracil-based adjuvant therapy in colon cancer. J Clin Oncol 2010;28:3219-26.